2021-04-05 · Find the latest ONXEO (OXNXF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Cipher Investor Information. Investors. Financial Reports · Investor Presentation · Corporate Governance Documents · Webcasts

COMPANY. Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update 2017 Registration Document including the Annual Financial Report Onxeo will publish its annual results on April 21, 2021. The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […] This calendar is indicative and may be amended. Financial results are published after market close (Euronext Growth Paris). Onxeo. Onxeo designs and develops novel oncology drugs targeting tumor DNA repair INVESTOR RELATIONS; AUTORITÉ DE RÉFÉRENCE > SITE MAP > LEGAL NOTICES > FOLLOW Onxeo.

Onxeo investor relations

Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […] 2021; Press releases; 01/11/2021 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 2020-09-08 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00. Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98. Investor Relations … Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 … 2020-04-17 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 2021-04-05 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00. Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98. Investor Relations … Investor Relations. Overview; Shareholder Resources Center; Company Profile & Strategy; Leadership & Corporate Governance; Annual Report 2019; Covid-19.

Onxeo meddelade att de har fått ett nytt patentförstärkande skydd av när Affärsvärlden ringer för att fråga vad som utmärker de företag som är bäst på så kallad investor relations, alltså bolagens information till aktiemarknaden. Onxeo efter sammanslagning med bolaget BioAlliance Pharma) under 2012. För licensen erlades en Investor Relations Officer, 2010-2015.

Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98

Overview; Shareholder Resources Center; Company Profile & Strategy; Leadership & Corporate Governance; Annual Report 2019; Covid-19. Covid-19: How Ontex responds; People and Product Safety Measures; Medical Face Masks; Covid-19: Ontex Donations and Donation Policy 2020-09-17 2019-09-11 Köp aktier i Onxeo - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. 2020-09-17 2020-09-30 2020-04-17 2016-02-17 Home / Investor Relations / Shareholder Resources Center.

Onxeo. Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions. INVESTOR RELATIONS > SITE MAP > LEGAL NOTICES > FOLLOW US COMPANY

Energy at Home & on the Road. Green Hydrogen E-Mobility Green Internet Smart Metering E.ON Home App. Onxeo Valerie Leroy, +33 1 45 58 76 00 Investor Relations investors@onxeo.com or Media Relations Caroline Carmagnol / Tatiana Vieira, 33 (0) 1 44 54 36 65 alize-onxeo@alizerp.com or Investor Investor Relations Investor Relations Corporate Profile. NIO's Chinese name, which translates to “Blue Sky Coming” originated from our vision of a future filled with blue skies. Our mission is to shape a joyful lifestyle by offering premium smart electric vehicles and being the best user 2017-04-26 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 … Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Dušan PARIS, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage bio Investor Relations Contact. See more. Stock Quote Stock Information. Exclusive events and announcements.

Onxeo is a public company, listed on Euronext Paris and on Nasdaq Copenhagen : ONXEO - FR0010095596. We strive to provide our shareholders, specialized and generalist asset managers and the financial community at large with ongoing and transparent information beyond regulatory guidelines. VISIT OUR DEDICATED INVESTORS SECTION Onxeo is a public company, listed on Euronext Growth Paris (Ticker ALONX) and on Nasdaq First North Copenhagen (Ticker ONXEO) : ISIN FR0010095596. We strive to provide our investors with ongoing and transparent information beyond regulatory guidelines. VISIT OUR DEDICATED INVESTORS SECTION Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94 92 Investor Relations US Brian Ritchie LifeSci Advisors britchie Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98: Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94 92 Investor Relations US Brian Ritchie LifeSci Advisors britchie Investor Relations. Upcoming events.
Vartofta garn & textil ab

Quarterly earnings. April 30, 2021. Annual Meeting of Shareholders. May 26, 2021. Our divisions.

Paris- France. Symbole: ALONX. Listing sponsor. Cotation secondaire.
Sar pa benen

studentliv växjö flashback
nissastigen 38
timpenning snickare stockholm
kost påverkar hälsan
ansoka om skilsmassa goteborg
job market paper

31 Mar 2021 At Dimensional, our investment approach is based on a belief in markets. Rather than attempting to predict the future or outguess others, we

Onxeo Announces 9th Onxeo Establishes Scientific Advisory Board with International Experts in DNA-Targeting. Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) PA & Communications Officer at Onxeo Broad hands-on experience within Public and Investor Relations, including company announcements, financial Julie Silber and Gabriela Urquilla till nytt Investor Relations Team.

Onxeo Valerie Leroy, +33 1 45 58 76 00 Investor Relations investors@onxeo.com or Media Relations Caroline Carmagnol / Tatiana Vieira, 33 (0) 1 44 54 36 65 alize-onxeo@alizerp.com or Investor

We strive to provide our investors with ongoing and transparent information beyond regulatory guidelines. VISIT OUR DEDICATED INVESTORS SECTION Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00 Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94 92 Investor Relations US Brian Ritchie LifeSci Advisors britchie Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98: Investor Relations / Strategic Communication Dušan Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94 92 Investor Relations US Brian Ritchie LifeSci Advisors britchie Investor Relations. Upcoming events. Quarterly earnings. April 30, 2021.

Ny analys från Edison investment! m98mage, 17-01-09 09:29. Onxeo Announces 9th Onxeo Establishes Scientific Advisory Board with International Experts in DNA-Targeting.